Stock PHIO PHIO PHARMACEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W5013

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-07-05 EDT 		5-day change 1st Jan Change
5.245 USD +0.33% Intraday chart for Phio Pharmaceuticals Corp. -15.78% -23.32%
07-02 Phio Pharmaceuticals Board Approves 1-For-9 Reverse Stock Split MT
05-28 Phio Pharmaceuticals Corp. Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b Clinical Study of Phio's Lead Compound PH-762 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 6.296 15.55 13.53 5.084 1.857 2.676 -
Enterprise Value (EV) 1 6.296 15.55 13.53 5.084 1.857 2.676 2.676
P/E ratio -0.49 x -1.4 x -0.96 x -0.44 x -0.15 x -0.32 x 0.15 x
Yield - - - - - - -
Capitalization / Revenue 300 x - - - - - 0.04 x
EV / Revenue 300 x - - - - - 0.04 x
EV / EBITDA - - - - - - -
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 6.2 53.5 125 127 271 510.2 -
Reference price 2 1,016 290.5 108.0 40.18 6.840 5.245 5.245
Announcement Date 20-03-26 21-03-25 22-03-22 23-03-22 24-04-01 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 0.021 - - - - - 75
EBITDA - - - - - - -
EBIT 1 -8.987 -8.793 -13.51 -11.46 -10.82 -9.6 62.8
Operating Margin -42,795.24% - - - - - 83.73%
Earnings before Tax (EBT) 1 -8.908 -8.794 -13.29 -11.48 -10.83 -9.6 62.8
Net income 1 -8.908 -8.794 -13.29 -11.48 -10.83 -9.6 47.7
Net margin -42,419.05% - - - - - 63.6%
EPS 2 -2,088 -207.4 -112.3 -90.90 -46.80 -16.38 34.02
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 20-03-26 21-03-25 22-03-22 23-03-22 24-04-01 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - -
EBITDA - - - - - - - - - - - -
EBIT 1 -3.45 -2.64 -2.521 -3.571 -2.73 - -2.776 -1.899 - -2.3 -2.5 -2.6
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -3.451 -2.642 -2.531 -3.576 -2.731 - -2.78 -1.895 - -2.3 -2.5 -2.6
Net income 1 -3.451 -2.642 -2.531 -3.576 -2.731 -2.549 -2.78 -1.895 -2.154 -2.3 -2.5 -2.6
Net margin - - - - - - - - - - - -
EPS 2 -28.08 -20.52 -20.52 -28.08 -21.78 -13.23 -10.26 -1.530 -4.230 -4.590 -4.140 -3.600
Dividend per Share - - - - - - - - - - - -
Announcement Date 22-03-22 22-05-12 22-08-11 22-11-10 23-03-22 23-08-10 23-11-09 24-04-01 24-05-09 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 20-03-26 21-03-25 22-03-22 23-03-22 24-04-01 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.245 USD
Average target price
36 USD
Spread / Average Target
+586.41%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PHIO PHARMACEUTICALS CORP. Stock Phio Pharmaceuticals Corp.
-23.32% 2.68M
MODERNA, INC. Stock Moderna, Inc.
+18.97% 45.34B
LONZA GROUP AG Stock Lonza Group AG
+41.98% 40.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.06% 37.92B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+31.15% 31.75B
CELLTRION, INC. Stock Celltrion, Inc.
-7.79% 27.71B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.32% 26.52B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+43.05% 13.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.28% 12.44B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.41% 11.26B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PHIO Stock
  4. Financials Phio Pharmaceuticals Corp.